Close Menu

NEW YORK (GenomeWeb) – Roche has ended its development, commercialization, and licensing agreement with Pacific Biosciences, according to documents filed with the US Securities and Exchange Commission. The termination will go into effect on Feb. 10, 2017.

The announcement of the termination hit PacBio's stock hard, sending the firm's shares down 40 percent to $4.11 in late Thursday morning trade on the Nasdaq.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.